RecruitingNCT04949282

Spanish Series of Patients Treated With the Radionuclide Lutetium177

SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177

Sponsor

Sociedad Española de Medicina Nuclear e Imagen Molecular

Enrollment

5,000 participants

Start Date

May 10, 2021

Study Type

OBSERVATIONAL

Conditions

Stomach Neoplasms Neuroendocrine Tumors Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Pancreatic Neoplasms Gastrointestinal Neoplasms Intestinal Neoplasms Gastrointestinal Disease Digestive System Diseases Intestinal Diseases Digestive System Neoplasms Neoplasms by Histologic Type Endocrine System Diseases Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Pancreatic Disease

Summary

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data on patients in Spain who are receiving lutetium-177 (a radioactive drug) as a treatment for certain cancers that have spread or cannot be surgically removed. The cancer must have special proteins on its surface (called somatostatin receptors) that allow the lutetium-177 to target and destroy cancer cells. **You may be eligible if...** - You are 18 or older - You have been diagnosed with an unresectable or metastatic, progressive tumor that tests positive for somatostatin receptors (this includes certain neuroendocrine tumors and prostate cancers, among others) - You have provided written informed consent **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this registry study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLutetium [177Lu] oxodotreotide/dotatate

Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

DEVICELutetium [177Lu] oxodotreotide/dotatate

Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

Locations(20)

Hospital Clínico Universitario de Santiago

Santiago de Compostela, A Coruña, Spain

Hospital Universitario Virgen de las Nieves

Granada, Andalusia, Spain

Hospital Unviersitari Son Espases

Palma de Mallorca, Balearic Islands, Spain

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario de Getafe

Getafe, Madrid, Spain

Hospital Univeritario Puerta de Hierro

Majadahonda, Madrid, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia, Spain

Clínica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Hospital Universitario de Burgos

Burgos, Spain

Hospital General Universitario de Ciudad Real

Ciudad Real, Spain

Hospital General Universitario Gregorio Marañón

Madrid, Spain

Hospital Universitario Ramon y Cajal

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario La Paz

Madrid, Spain

Hospital Universitario HM Sanchinarro

Madrid, Spain

Hospital Universitario de Navarra

Pamplona, Spain

Hospital Universitario Doctor Peset

Valencia, Spain

Hospital Universitario La Fe

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04949282

Related Trials

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT033661161 location

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT000710451 location

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NCT014434682 locations

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

NCT0731416428 locations

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT070819972 locations